Under the agreement, Gulf Coast’s primary product sales and distribution focus will be InoLife Technologies’ Genetic Predisposition Test.

Gulf Coast will also distribute InoLife Technologies’ Cytochrome CYP2C19drug metabolism analysis, which determines if a patient has a genetic variation that may reduce the effectiveness of Plavix.

InoLife Technologies president and CEO Gary Berthold said Gulf Coast will provide their company with a large-scale distribution warehouse and a North American-wide sales force to accelerate market penetration of DNA-based product line.

Gulf Coast president and CEO Ken Ritchey said they are proud to have been selected by InoLife as its strategic venture partner.